SCHEMBL11943819

SCHEMBL11943819

Nc1cc(CN2CCN(c3cnn(-c4cccc(Cl)c4)c(=O)c3OC3CCCC3)CC2)ccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.42
▸ CYP3A4 P08684 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ PPARG P37231 1/20 0.38
▸ NCOA2 Q15596 1/20 0.38
▸ NCOA1 Q15788 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ NCOA3 Q9Y6Q9 1/20 0.38
▸ USP2 O75604 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ THRB P10828 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ HTR1A P08908 2/20 0.38
▸ DRD2 P14416 2/20 0.38
▸ MAPT P10636 2/20 0.37
▸ TSHR P16473 2/20 0.37
▸ HTR2A P28223 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943822 0.88 LMNA (0.52) LMNACYP3A4POLBCYP2C19PPARG
SCHEMBL11943817 0.84 CYP3A4 (0.46) LMNACYP3A4POLBCYP2C19PPARG
SCHEMBL17058131 0.81 ALDH1A1 (0.42) LMNACYP3A4POLBCYP2C19PPARG
SCHEMBL14899753 0.80 SMN1; SMN2 (0.48) LMNACYP3A4POLBCYP2C19PPARG
SCHEMBL11944494 0.79 POLB (0.52) LMNACYP3A4POLBCYP2C19PPARG
SCHEMBL11943831 0.79 NPBWR1 (0.52) LMNAUSP2KDM4EALDH1A1THRB
SCHEMBL11945245 0.78 POLB (0.46) LMNACYP3A4POLBCYP2C19PPARG
SCHEMBL11945565 0.78 TP53 (0.47) LMNACYP3A4POLBCYP2C19PPARG
SCHEMBL11945215 0.78 MAPT (0.57) LMNACYP3A4POLBCYP2C19PPARG
SCHEMBL17057929 0.78 POLB (0.42) LMNACYP3A4POLBCYP2C19PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA LMNA 929/4885CYP3A4 281/4885POLB 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback